BR112023017274A2 - Vacina contra metapneumovírus humano - Google Patents

Vacina contra metapneumovírus humano

Info

Publication number
BR112023017274A2
BR112023017274A2 BR112023017274A BR112023017274A BR112023017274A2 BR 112023017274 A2 BR112023017274 A2 BR 112023017274A2 BR 112023017274 A BR112023017274 A BR 112023017274A BR 112023017274 A BR112023017274 A BR 112023017274A BR 112023017274 A2 BR112023017274 A2 BR 112023017274A2
Authority
BR
Brazil
Prior art keywords
human metapneumovirus
against human
vaccine against
respiratory system
vaccine composition
Prior art date
Application number
BR112023017274A
Other languages
English (en)
Inventor
Andreas Meinke
Fabien Perugi
Urban Lundberg
Original Assignee
Valneva Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Se filed Critical Valneva Se
Publication of BR112023017274A2 publication Critical patent/BR112023017274A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

vacina contra metapneumovírus humano. a presente invenção se refere a uma composição de vacina para prevenir e/ou tratar uma infecção do sistema respiratório, como uma infecção do sistema respiratório por metapneumovírus humano. esta composição de vacina compreende uma, duas ou mais proteínas f de metapneumovírus humano (hmpv) modificadas ou variantes das mesmas providas em uma forma de conformação de fusão, pré-fusão.
BR112023017274A 2021-04-09 2022-04-08 Vacina contra metapneumovírus humano BR112023017274A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21167609 2021-04-09
PCT/EP2022/059492 WO2022214678A2 (en) 2021-04-09 2022-04-08 Human metapneumo virus vaccine

Publications (1)

Publication Number Publication Date
BR112023017274A2 true BR112023017274A2 (pt) 2023-11-14

Family

ID=75441775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017274A BR112023017274A2 (pt) 2021-04-09 2022-04-08 Vacina contra metapneumovírus humano

Country Status (10)

Country Link
US (1) US20240181034A1 (pt)
EP (2) EP4319804A2 (pt)
JP (1) JP2024522385A (pt)
KR (1) KR20230167017A (pt)
CN (1) CN117279659A (pt)
AU (1) AU2022255923A1 (pt)
BR (1) BR112023017274A2 (pt)
CA (1) CA3210412A1 (pt)
MX (1) MX2023010370A (pt)
WO (2) WO2022214678A2 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
ES2288555T3 (es) 2001-05-21 2008-01-16 Intercell Ag Moleculas de oligodesoxinucleotidos inmunoestimuladores.
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
SI3106176T1 (en) 2011-12-06 2018-04-30 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2016103238A1 (en) * 2014-12-24 2016-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus f proteins and their use
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
AU2020277661A1 (en) * 2019-05-20 2021-10-21 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection

Also Published As

Publication number Publication date
WO2022214685A3 (en) 2023-03-09
CN117279659A (zh) 2023-12-22
EP4319804A2 (en) 2024-02-14
WO2022214685A2 (en) 2022-10-13
AU2022255923A1 (en) 2023-08-31
CA3210412A1 (en) 2022-10-13
MX2023010370A (es) 2023-09-12
KR20230167017A (ko) 2023-12-07
WO2022214678A2 (en) 2022-10-13
US20240181034A1 (en) 2024-06-06
EP4319802A2 (en) 2024-02-14
JP2024522385A (ja) 2024-06-19
WO2022214678A3 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
BR112018010505A2 (pt) mistura de oligossacarídeos de leite humano (hmos)
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
BR112014021101A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
BR112017018328A2 (pt) anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
BR112014018767A8 (pt) Compostos de pirroldicarboxamidas fundidas e composição farmacêutica que os compreende
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112015012711A2 (pt) método de produção de uma vacina de mycoplasma
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
BR112016029437A2 (pt) métodos para tratamento e prevenção de doenças de instabilidade vascular
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
BR112023017274A2 (pt) Vacina contra metapneumovírus humano
BR112018016721A2 (pt) uso de di-hidrogeno fosfato de {6-[(e)-3-{metil[(3-metil-1-benfofuran-2-iol)metil]amino)-3-xopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)-il}metila e composição farmacêutica para tratamento de infecções bacterianas associadas ao pé diabético
MX363044B (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
BR112017009501A2 (pt) método para tratar uma infecção por hcv, método para curar uma infecção por hcv, e, composição farmacêutica.